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Latent infection of primary CD34+ progenitor cells by human cytomegalovirus (HCMV) results
in their increased survival in the face of pro-apoptotic signals. For instance, we have shown
previously that primary myeloid cells are refractory to FAS-mediated killing and that cellular
IL-10 (cIL-10) is an important survival factor for this effect. However, how cIL-10 mediates this
protection is unclear. Here, we have shown that cIL-10 signalling leading to upregulation of the
cellular factor PEA-15 mediates latency-associated protection of CD34+ progenitor cells from
the extrinsic death pathway.
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Human cytomegalovirus (HCMV), like all herpesviruses,
has both a lytic and a latent phase to its infectious cycle.
During the lytic life cycle, all of the viral genes are
expressed in a temporal fashion. This results in major
effects on the host cell, which include multiple strategies
for host immune evasion (Amsler et al., 2013; Jackson
et al., 2011; McSharry et al., 2012; Noriega et al., 2012;
Weekes et al., 2014). In contrast, during latent infection
in, for example, cells of the myeloid lineage, there is a far
more restricted transcription programme (Goodrum
et al., 2002; Rossetto et al., 2013; Slobedman & Mocarski,
1999). Although the functions of these latency-associated
gene products during latency have not yet been fully eluci-
dated, it has been the focus of a number of studies (Avdic
et al., 2011; Keyes et al., 2012; Mason et al., 2013; Poole
et al., 2013; Reeves & Sinclair, 2010; Rossetto et al., 2013;
Weekes et al., 2013), and it is now clear that latent infection
of myeloid cells with HCMV can have profound effects on
the latently infected cell.
For example, it has been shown that during latent infection
there are a number of changes to the cellular micro-
RNAome (Fu et al., 2014; Poole, 2011), as well as changes
in the cellular secretome (Mason et al., 2012), and recently
there have been a number of innate immune evasion func-
tions found associated with short-term experimental
HCMV latency in monocytes (Noriega et al., 2014). The
functions of some of the changed identified factors have
been demonstrated (Mason et al., 2012, 2013; Poole,
2011; Poole et al., 2013) and at least one, IL-10, has signifi-
cant pro-life effects on the latent cell (Mason et al., 2012;
Poole, 2011), including the inhibition of FAS-mediated
apoptosis (Poole, 2011). The latency-induced upregulation
of the pro-life factor IL-10 is mediated in part by
downregulation of the microRNA hsa-miR-92a and up-
regulation of the anti-apoptotic factor Bcl2 (Poole, 2011).
In addition to the upregulation of Bcl2, a full transcrip-
tome analysis of monocytes latently infected with HCMV
found changes in the levels of the related family member
Mcl1 (Chan et al., 2010). It is likely that this myeloid
factor plays an important anti-apoptotic role in signalling
mediated by virus binding to the cell surface, as well as
during HCMV latency (Reeves et al., 2012). Another
study of the complete HCMV latent transcriptome in gran-
ulocyte–macrophage precursors also identified upregula-
tion in mRNA levels of the anti-apoptotic factor PEA-15
(Slobedman & Mocarski, 1999), although changes in pro-
tein levels have not been confirmed. Interestingly, PEA-15
can be upregulated by IL-10 (Todaro et al., 2006); however,
whether there is a link between the observed upregulation
of IL-10 and PEA-15 mRNAs during HCMV latency has
not so far been demonstrated.
Therefore, we initially tested whether PEA-15 was upregu-
lated at the protein level in primary CD34+ cells during
HCMV latency. Fig. 1(a) shows that CD34+ cells infected
with HCMV as described previously (Poole et al., 2014b)
and left to establish a latent infection contained, as expected
(Poole et al., 2014b), undetectable levels of IE72 RNA in the
presence of detectable LUNA protein when tested by reverse
transcriptase (RT)-PCR confirming that these cells had all
the hallmarks of latent infection (Mason et al., 2012;
Reeves et al., 2005). This was in contrast to lytic infection
where IE72 RNA was detectable (Fig. 1a). Consequently,
we also confirmed that the latency-associated increase in
PEA-15 protein in CD34+ cells was also reflected at the
level of mRNA (analysed using Qiagen RT-qPCR primers
and a SYBR Green kit). Fig. 1(b) shows that quantitative
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RT-PCR analysis, as described previously (Poole, 2011), also
showed upregulation of PEA-15 mRNA in latently infected
CD34+ cells. Western blotting of cell lysate for PEA-15
(using an antibody from Cell Signalling) showed that, com-
pared with the b-actin control (using an antibody from
Abcam), there was a robust increase in the levels of PEA-15
protein following the establishment of latency in CD34+
myeloid progenitor cells. Our observations that PEA-15 is
increased during latent infection of CD34+ progenitors at
the level of the protein is consistent with a previous tran-
scriptome analysis of latently infected granulocyte–macro-
phage progenitors (Slobedman & Mocarski, 1999).
The data, so far, demonstrated that PEA-15 was upregulated
during latency at both the mRNA and protein levels. How-
ever, in order to determine whether PEA-15 was directly
involved in the ability of cellular IL-10 (cIL-10) to protect
CD34+ cells from extrinsic death signals, it was necessary
to assess the protection of CD34+ cells by cIL-10 in the
absence of PEA-15. Unfortunately, primary CD34+ cells
are notoriously difficult to manipulate by transfection, so
we turned to the CD34+ cell line Kasumi-3, which is easily
transfectable (Amaxa, Lonza; all transfections had an
efficiency of .95%, demonstrated with green fluorescent
control) and reproduces many of the major aspects of
latent HCMV infection. Importantly, although the
Kasumi-3myeloblastic cell lines appear to show some differ-
ences with respect to primary CD34+ cells in the establish-
ment of latent infection with the AD169 laboratory isolate
of HCMV, they fully support latent infection with clinical
isolates of HCMV and are equivalent to primary CD34+
cells in this respect (Albright & Kalejta, 2013). Indeed,
latent infection of Kasumi-3 cells results in all the hallmarks
of latent infection observed in primary CD34+ cells, such as
maintenance of the viral genome with concomitant lack of
lytic IE72 expression but the presence of expression of the
latency-associated LUNA gene (Albright & Kalejta, 2013;
O’Connor & Murphy, 2012).
Initially, we confirmed that Kasumi-3 cells supported latent
infection and reactivation in our hands by using a TB40E
strain of HCMV, which expresses the lytic antigen IE2
fused to red fluorescent protein (RFP) (Fig. 2). Fig. 2
shows that after 3 days of infection there was no detectable
IE2 protein (Fig. 2, latent), yet these cells were still able to
reactivate virus after differentiation (Fig. 2, reactivation),
again consistent with previous studies of IE72 protein
expression in these cells (O’Connor & Murphy, 2012).
As expected, cells that were differentiated prior to infection
were permissive (Fig. 2, lytic). Therefore, we chose to use a
3-day time period for latent infection for subsequent small
interfering RNA (siRNA) transfection analyses.
Having established that Kasumi-3 cells can be used as a
model of latent infection and can also be manipulated by
transfection, we tested the effect of removing PEA-15 on
cell survival after extrinsic pro-death signals during latency
by RNA interference knockdown. Consistent with previous
findings for primary CD34+ cells (Poole, 2011), as
expected, uninfected Kasumi-3 cells were clearly sensitive
to FAS-mediated killing (Fig. 3a, lane 2), with minimal
levels of apoptosis in the absence of FAS (Fig. 3a, lane 1).
FAS-mediated killing was also inhibited by the pan-caspase
inhibitor Z-VAD-FMK (Fig. 3A, lane 3), and control
siRNA itself did not induce cell death in the presence of
HCMV latent infection (Fig. 3a, lane 4). Also, consistent
with previous analyses using primary CD34+ cells, latent
infection of Kasumi-3 cells resulted in their protection
from FAS-mediated killing (Fig. 3a, lane 5). To test
whether PEA-15 was important for this resistance to
FAS-mediated killing, we repeated the killing assay in
cells in which we had knocked down PEA-15. Fig. 3(a,
lane 8) shows that, in contrast to latently infected cells
that had been treated with control siRNAs (Fig. 3a, lane
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Fig. 1. PEA-15 is upregulated during HCMV latency at the mRNA and protein levels. (a) Primary CD34+ myeloid progenitor cells
were either uninfected (mock) or latency was established for 10 days and confirmed by reverse transcription (RT)-PCR analysis
(right-hand panels). As a positive control, RT-PCR was also carried out on lytically infected fibroblasts (left-hand panel). (b, c) The
cells were harvested for quantitative RT-PCR analysis for PEA-15 transcripts (b) or lysed for Western blot analysis for PEA-15
relative to a b-actin control (c). Data are representative of three replicates. Results in (b) are means¡SD. HFF, human foreskin
fibroblasts; IE, immediate early; UL82as, UL82 anti-sense; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.
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5, 22% apoptosis), latently infected cells that had been
treated with siRNAs to PEA-15 were sensitive to FAS-
mediated cell killing (Fig. 3a, lane 8, 79% apoptosis).
Thus, the removal of PEA-15 from cells carrying latent
HCMV prevented their resistance to FAS-mediated killing.
These data argued that the latency-associated resistance of
these CD34+myelomonocytic cells to FAS-mediated killing
was, at least in part, directly due to the presence of PEA-15.
The effectiveness of PEA-15 removal from transfected
latently infected cells using siRNAs was confirmed by Wes-
tern blotting (Fig. 3b, anti-b-actin and anti-PEA-15 anti-
bodies from Abcam); although PEA-15 was undetectable in
untreated Kasumi-3 cells in our hands, when PEA-15 was
induced by the establishment of HCMV latency, transfection
with PEA-15-specific siRNAs in these cells eliminated
PEA-15 protein expression (Fig. 3b).
Given that latency was not established in 100% of the
infected cell population, the very high percentages of cells
resistant to FAS-mediated killing observed in the presence
of PEA-15 during latency suggested that the mechanism by
which PEA-15 confers protection is likely to be mediated
via a secreted factor that would also protect uninfected
bystander cells. It is known that the latency-induced secre-
tome contains latency-induced cIL-10 (Mason et al., 2012)
and that this latency-associated increase in cIL-10 helps
maintain latent viral genome carriage by preventing cell
death (Poole, 2011; Weber-Nordt et al., 1996); it also
known that cIL-10 causes upregulation of PEA-15
(Todaro et al., 2006). Consequently, we tested whether
cIL-10 was required for the upregulation of PEA-15
during HCMV latency. To test this, a cIL-10 neutralization
assay was carried out (antibodies from R&D Systems, neu-
tralization carried out in accordance with the manufac-
turer’s instructions). Fig. 3(c) shows that treatment of
latently infected CD34+ cells with a neutralizing anti-
cIL-10 antibody resulted specifically in substantially
decreased levels of PEA-15 protein. Importantly, the cIL-
10-neutralizing antibodies used were specific for cIL-10
and did not target the HCMV-encoded viral IL-10 homo-
logue. Consequently, this argued that it is cIL-10, and not
viral IL-10, that is the major factor required for the
observed upregulation of the pro-life factor PEA-15.
PEA-15 is an anti-apoptotic molecule that potently regu-
lates FAS/tumour necrosis factor receptor 1-induced apop-
tosis. This is achieved by targeting the Fas-associated death
domain protein (FADD), an early effector of the death-
inducing signalling complex (Todaro et al., 2006). Conse-
quently, latency-associated increases in PEA-15 would
have profound effects on extrinsic pro-death signalling to
the cell. Our observations that neutralizing antibodies to
cIL-10 reduced the latency-associated increase in PEA-15
argue strongly that the increase in PEA-15 during latency
was directly mediated by cIL-10. These data fit with the
observation that cIL-10 causes upregulation of PEA-15
(Todaro et al., 2006). Additionally, we have shown pre-
viously that cIL-10 from the latency-associated secretome
helps latent cell survival (Poole, 2011; Poole et al., 2014a;
Mason et al., 2012); removal of cIL-10 from latently
infected CD34+ cells results in increased FAS-mediated
apoptosis (Poole, 2011).
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Fig. 2. Latent infection is established in Kasumi-3 cells at 3 days
post-infection. Undifferentiated Kasumi-3 cells were infected with
IE2–RFP tagged HCMV TB40E strain at an m.o.i. of 3.0 for
3 days before being analysed (latent) or following the establish-
ment of latency for 3 days. Kasumi-3 cells were treated with
phorbol 12-myristate 13-acetate as described previously
(O’Connor & Murphy, 2012) for 48 h before analysis (reactiva-
tion). Finally, prior to infection, cells were differentiated with phor-
bol 12-myristate 13-acetate for 48 h (lytic). Cells were counted
and presented graphically (a) and were analysed directly by
immunofluorescence (b). Data in (a) represent triplicate samples
of six fields of view (means¡SD).
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In conclusion, our data suggest that latent HCMV infection
of CD34+ cells results in changes in the levels of anti-
apoptotic cellular factor PEA-15, which are mediated via
cIL-10 to enhance cell survival. We believe that this is
further evidence that latent carriage of HCMV results in
profound changes to the cell, which, without concomitant
and coordinated changes in cell death signalling pathways,
would lead to loss of the latently infected cell population.
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